Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells

In conclusion, we demonstrated that proteasome inhibitors (BZM or MG132) attenuated MTX-induced ICD, suggesting that proteasome activation was required for MTX-induced ICD.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research